Managing Urinary Incontinence And Latent Adult Onset Diabetes

The presence of islet autoantibodies and gradual β-cell decline distinguish LADA, and accurate early identification is critical for tailored treatment and improved outcomes.

Urinary incontinence (UI) is a common, often underreported condition. It negatively impacts physical, psychological, and social well-being. Given the potential for autonomic neuropathy and urogenital complications in diabetic patients, the co-occurrence of LADA and UI warrants clinical attention.

Significance of Co-management

Understanding and managing both LADA and UI concurrently is essential, as their combined burden can significantly impair quality of life. A multidisciplinary approach involving endocrinologists, primary care providers, and urologists is recommended to address the multifaceted needs of these patients effectively.

Understanding Latent Autoimmune Diabetes in Adults (LADA)

Latent autoimmune diabetes in adults (LADA) is a slowly progressing form of autoimmune diabetes that commonly emerges in individuals over 30 years of age. Initially, LADA often presents with clinical features resembling type 2 diabetes (T2D), such as mild hyperglycemia and the absence of ketoacidosis, leading to frequent misdiagnosis. However, unlike T2D, LADA is characterized by the presence of pancreatic islet autoantibodies, particularly glutamic acid decarboxylase antibodies (GADA). It is now recognized by the American Diabetes Association as a subtype of type 1 diabetes mellitus (T1D), accounting for approximately 2%–12% of diabetes cases.

In LADA (Latent Autoimmune Diabetes in Adults), the body's own immune system mistakenly attacks the cells in the pancreas that make insulin (called beta cells). This attack is mainly carried out by special immune cells called T-cells. As a result, the pancreas gradually loses its ability to produce insulin. Research has shown that people with LADA have immune cells in their blood that can interfere with insulin production, and tissue samples from the pancreas confirm that these immune cells are causing inflammation and damage. LADA also features reduced numbers and impaired function of regulatory T cells, contributing to a dysregulated immune response. Additionally, gut microbiota alterations may influence the immune environment, further contributing to the disease.

Etiology and Epidemiology of LADA

LADA (Latent Autoimmune Diabetes in Adults) is caused by a mix of genetic and immune system factors. Just like in type 1 diabetes, people with certain genes—especially HLA genes—are more likely to develop LADA. These genes are involved in the immune system, which mistakenly attacks the cells in the pancreas that produce insulin. The exact triggers are still unclear, but lifestyle factors like obesity, sugary drinks, and smoking may increase the risk, especially in people who also have a higher body weight. On the other hand, regular exercise, eating fatty fish, and moderate alcohol use may help protect against LADA.

LADA is the most common type of adult-onset autoimmune diabetes, affecting around 9% of adults with diabetes worldwide. Most people with LADA test positive for at least one diabetes-related autoantibody.

Urinary Incontinence: Types, Prevalence, and Risk Factors

Urinary incontinence (UI) means the unintentional loss of urine. There are different types: stress incontinence (leakage during coughing, sneezing, or lifting), urge incontinence (a sudden, strong urge to urinate followed by leakage), and mixed incontinence (a combination of both).

In people with latent autoimmune diabetes in adults (LADA)—a slow-progressing form of type 1 diabetes—UI is more common, especially as the disease affects the bladder over time. The immune system attack seen in LADA also weakens defenses, making infections like urinary tract infections (UTIs) more frequent. Over time, high blood sugar can damage nerves that control the bladder, leading to diabetic bladder dysfunction. This can show up as needing to pee urgently or often, or having difficulty fully emptying the bladder.

UI is more common in older adults, and men with diabetes (including LADA) are at increased risk. Other factors that raise the risk include age, being overweight, and other health issues like nerve damage or prostate problems.

Managing blood sugar, maintaining a healthy weight, and addressing bladder symptoms early are key to improving quality of life and preventing complications.

Diagnostic Approaches 

Diagnosing LADA (Latent Autoimmune Diabetes in Adults) begins with blood tests that check for specific autoantibodies, especially GAD antibodies (GADA), which are found in about 90% of LADA patients. Measuring C-peptide levels also helps assess how much insulin your pancreas is still producing—low or declining levels support a diagnosis of LADA. Additional tests like HbA1c and fasting glucose are used to evaluate blood sugar control.

Evaluating Urinary Incontinence (UI):
To diagnose UI in people with LADA, doctors take a detailed medical history, recommend keeping a bladder diary, and may perform urodynamic studies to assess bladder function. Urine tests are also essential to detect infections, especially since diabetes weakens the immune system, making infections more common.

A full assessment is crucial. Understanding both LADA and UI allows healthcare providers to tailor treatment plans that manage blood sugar and protect bladder health, ultimately improving quality of life.

Management Strategies

Lifestyle Modifications

Making healthy lifestyle changes is one of the most effective ways to manage both LADA (Latent Autoimmune Diabetes in Adults) and urinary incontinence (UI). If you are overweight, even modest weight loss—around 5% to 10% of your body weight—can help improve how your body uses insulin and may ease symptoms of both conditions. Physical activity like walking, swimming, or cycling for at least 150 minutes a week can help your body use insulin better and may reduce incontinence episodes. Avoiding sugary drinks, smoking, and processed foods is also important. These steps can delay the need for insulin therapy in LADA and improve bladder control, especially in people who are overweight or inactive.

Pharmacological Interventions

LADA is a unique form of diabetes that often requires insulin treatment. Many patients eventually need insulin to maintain healthy blood sugar levels. Some people may start insulin soon after diagnosis, especially if their pancreas is already producing very little insulin. Studies show that starting insulin early may help preserve the remaining insulin-producing cells, which is crucial to slow disease progression.

While metformin (a medication that improves insulin sensitivity) is often used early on, its long-term benefit in LADA is unclear. Medications called DPP-4 inhibitors (like sitagliptin) have shown potential to support insulin production and help manage blood sugar safely. However, drugs like sulfonylureas are not recommended, as they may harm insulin-producing cells in the pancreas.

Pelvic Floor Muscle Training

For managing urinary incontinence, especially in people with diabetes, strengthening your pelvic floor muscles can be a game-changer. Kegel exercises are simple movements that involve tightening the muscles used to stop urinating. Doing these exercises daily can improve bladder control and reduce leaks. Studies have shown that pelvic floor training can significantly improve quality of life for those living with UI, especially men after prostate-related treatments or with diabetic nerve damage.

Patient Education and Support

Effective management of Latent Autoimmune Diabetes in Adults (LADA) and urinary incontinence (UI) hinges on comprehensive patient education and robust support systems. Encouraging open discussions about UI can reduce stigma, fostering early intervention and improved outcomes. Patients with LADA require detailed education on their condition, emphasizing the necessity of strict glycemic control to prevent complications. This includes guidance on medical nutrition, medication adherence, glucose self-monitoring, and recognizing signs of microvascular and cardiovascular issues. Particularly, those on sodium-glucose cotransporter-2 (SGLT2) inhibitors should be informed about the risk of ketoacidosis and the importance of ketone monitoring. 

Access to educational resources  can empower patients with lifestyle tips and treatment options. Additionally, participation in support groups and counseling services offers emotional backing and shared experiences, which are crucial in managing chronic conditions like LADA and UI. These platforms provide a sense of community, reduce feelings of isolation, and encourage adherence to treatment plans.

Conclusion 

Managing Latent Autoimmune Diabetes in Adults (LADA) alongside urinary incontinence (UI) necessitates an integrated approach that addresses both metabolic control and urological health. Early diagnosis, patient education, and coordinated care are pivotal in mitigating complications and enhancing quality of life.

For men experiencing UI, especially those with limited mobility, the QuickChange Wraps offers a practical solution.  For those seeking support, we invite you to purchase a 10 Count Trial Pack here or request a professional-use sample pack for healthcare institutions here.

References:

1. Awata, T., Shimada, A., Maruyama, T., Oikawa, Y., Yasukawa, N., Kurihara, S., ... Kobayashi, T. (2017). Possible long-term efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for slowly progressive type 1 diabetes (SPIDDM) in the stage of non-insulin-dependency: An open-label randomized controlled pilot trial (SPAN-S). Diabetes Therapy, 8(5), 1123–1134. https://doi.org/10.1007/s13300-017-0299-7

2. Brophy, S., Davies, H., Mannan, S., Brunt, H., & Williams, R. (2011). Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Database of Systematic Reviews, 2011(9), CD006165. https://doi.org/10.1002/14651858.CD006165.pub3

3. Buzzetti, R., Tuomi, T., Mauricio, D., Pietropaolo, M., Zhou, Z., Pozzilli, P., & Leslie, R. D. (2020). Management of latent autoimmune diabetes in adults: A consensus statement from an international expert panel. Diabetes, 69(10), 2037–2047. https://doi.org/10.2337/dbi20-0017

4. Carlsson, S. (2019). Etiology and pathogenesis of latent autoimmune diabetes in adults (LADA) compared to type 2 diabetes. Frontiers in Physiology, 10, 320. https://doi.org/10.3389/fphys.2019.00320

5. Chiu, H. K., Tsai, E. C., Juneja, R., Stoever, J., Brooks-Worrell, B., Goel, A., & Palmer, J. P. (2007). Equivalent insulin resistance in latent autoimmune diabetes in adults (LADA) and type 2 diabetic patients. Diabetes Research and Clinical Practice, 77(2), 237–244. https://doi.org/10.1016/j.diabres.2006.12.013

6. Fourlanos, S., Perry, C., Stein, M. S., Stankovich, J., Harrison, L. C., & Colman, P. G. (2006). A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care, 29(5), 970–975. https://doi.org/10.2337/diacare.295970

7. Golbidi, S., & Laher, I. (2010). Bladder dysfunction in diabetes mellitus. Frontiers in Pharmacology, 1, 136. https://doi.org/10.3389/fphar.2010.00136

8. Löfvenborg, J. E., Andersson, T., Carlsson, P. O., Dorkhan, M., Groop, L., Martinell, M., ... Carlsson, S. (2014). Fatty fish consumption and risk of latent autoimmune diabetes in adults. Nutrition & Diabetes, 4(10), e139. https://doi.org/10.1038/nutd.2014.36

9. Qasrawi, H., Tabouni, M., Almansour, S. W., Ghannam, M., Abdalhaq, A., Abushamma, F., Koni, A. A., & Zyoud, S. H. (2022). An evaluation of lower urinary tract symptoms in diabetic patients: A cross-sectional study. BMC Urology, 22(1), 178. https://doi.org/10.1186/s12894-022-01133-1

10. Rajkumar, V., & Levine, S. N. (2024). Latent autoimmune diabetes. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557897/

11. Zhang, M., Lin, S., Yuan, X., Lin, Z., & Huang, Z. (2019). HLA-DQB1 and HLA-DRB1 variants confer susceptibility to latent autoimmune diabetes in adults: Relative predispositional effects among allele groups. Genes, 10(9), 710. https://doi.org/10.3390/genes10090710